Literature DB >> 24679866

Risk factors for febrile urinary tract infection in infants with prenatal hydronephrosis: comprehensive single center analysis.

Piotr Zareba1, Armando J Lorenzo2, Luis H Braga3.   

Abstract

PURPOSE: We assessed risk factors for urinary tract infection in children with prenatal hydronephrosis
MATERIALS AND METHODS: We identified 376 infants with prenatal hydronephrosis in an institutional database. The occurrence of febrile urinary tract infection in the first 2 years of life was ascertained by chart review. Febrile urinary tract infection was defined as a positive culture from a catheterized urine specimen in a patient with a fever of 38.0C or greater. Multivariate logistic regression was used to assess gender, circumcision status, hydronephrosis grade, vesicoureteral reflux grade and antibiotic prophylaxis as predictors of the risk of urinary tract infection.
RESULTS: Included in analysis were 277 males and 99 females. Hydronephrosis was high grade in 128 infants (34.0%) and vesicoureteral reflux was present in 79 (21.0%). Antibiotic prophylaxis was prescribed in 60.4% of patients, preferentially to females vs males (70.7% vs 56.7%), those with high vs low grade hydronephrosis (70.3% vs 55.2%) and those with vs without vesicoureteral reflux (96.2% vs 50.8%). On multivariate analysis there was an association between high grade hydronephrosis and an increased risk of urinary tract infection (adjusted OR 2.40, 95% CI 1.26-4.56). Females (adjusted OR 3.16, 95% CI 0.98-10.19) and uncircumcised males (adjusted OR 3.63, 95% CI 1.18-11.22) were also at higher risk than circumcised males. Antibiotic prophylaxis was not associated with a decreased risk of urinary tract infection (adjusted OR 0.93, 95% CI 0.45-1.94).
CONCLUSIONS: High grade hydronephrosis, female gender and uncircumcised status in males are independent risk factors for febrile urinary tract infection in infants with prenatal hydronephrosis. Antibiotic prophylaxis did not reduce the risk of urinary tract infection in the study group.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  antibiotic prophylaxis; hydronephrosis; kidney; prenatal diagnosis; urinary tract infections

Mesh:

Year:  2014        PMID: 24679866     DOI: 10.1016/j.juro.2013.10.035

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Antibiotic prophylaxis for prevention of urinary tract infections in prenatal hydronephrosis: An updated systematic review.

Authors:  Bethany Easterbrook; John-Paul Capolicchio; Luis H Braga
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

Review 2.  Continuous antibiotic prophylaxis in the setting of prenatal hydronephrosis and vesicoureteral reflux.

Authors:  Nathan C Wong; Martin A Koyle; Luis H Braga
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

3.  Canadian Urological Association guideline on the care of the normal foreskin and neonatal circumcision in Canadian infants (abridged version).

Authors:  Sumit Dave; Kourosh Afshar; Luis H Braga; Peter Anderson
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

4.  Canadian Urological Association guideline on the care of the normal foreskin and neonatal circumcision in Canadian infants (full version).

Authors:  Sumit Dave; Kourosh Afshar; Luis H Braga; Peter Anderson
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

5.  It is not "Just Circumcision".

Authors:  Ebru Yesildag
Journal:  Pak J Med Sci       Date:  2015 Jul-Aug       Impact factor: 1.088

6.  From Research Question to Conducting a Randomized Controlled Trial on Continuous Antibiotic Prophylaxis in Prenatal Hydronephrosis: A Rational Stepwise Process.

Authors:  Luis H Braga; Bethany Easterbrook; Kizanee Jegatheeswaran; Armando J Lorenzo
Journal:  Front Pediatr       Date:  2016-03-30       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.